281,969 Shares in Abbott Laboratories $ABT Bought by MV Capital Management Inc.

MV Capital Management Inc. acquired a new position in Abbott Laboratories (NYSE:ABT) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 281,969 shares of the healthcare product maker’s stock, valued at approximately $35,328,000. Abbott Laboratories accounts for approximately 3.4% of MV Capital Management Inc.’s holdings, making the stock its 6th biggest position.

Other hedge funds have also recently modified their holdings of the company. J. Stern & Co. LLP increased its stake in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Norges Bank bought a new stake in Abbott Laboratories during the fourth quarter worth about $2,938,892,000. Invesco Ltd. grew its holdings in Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the period. Ninety One UK Ltd bought a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $336,815,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after purchasing an additional 2,402,408 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Monday, April 27th. The shares were acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT opened at $88.48 on Friday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The company has a market capitalization of $154.12 billion, a P/E ratio of 24.78, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The firm has a 50 day moving average of $90.39 and a 200 day moving average of $106.73. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the prior year, the firm posted $1.09 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Analysts Set New Price Targets

ABT has been the topic of a number of analyst reports. Leerink Partners dropped their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Raymond James Financial lowered their price objective on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Sanford C. Bernstein dropped their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Wells Fargo & Company cut their target price on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Finally, Evercore reduced their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $118.30.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.